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Abstract
Objective: C-reactive protein (CRP) is an independent risk factor for renal 
allograft loss and predicts all-cause mortality in kidney transplantation 
patients. Metabolic syndrome has also been associated with increased 
mortality in kidney transplantation patients. The aim of this study was 
to investigate the relationship between CRP and metabolic syndrome in 
kidney transplantation patients.
Materials and Methods: Fasting blood samples were obtained from 55 kid-
ney transplantation patients. Metabolic syndrome and its components were 
defined using diagnostic criteria from the International Diabetes Federation.
Results: In total, 13 kidney transplantation patients (23.6%) had meta-
bolic syndrome. Fasting CRP levels positively correlated with metabolic 
syndrome (p = 0.001). Univariate linear regression analysis indicated that 
fasting serum CRP values were positively correlated with body weight 
(p = 0.001), waist circumference (p = 0.008), body mass index (p < 0.001), 
and body fat mass (p = 0.042). Multivariate forward stepwise linear regres-
sion analysis of the significant variables showed that body mass index 
(β = 0.455, R2 = 0.207, p < 0.001) was an independent predictor of serum 
CRP levels in kidney transplantation patients.
Conclusion: CRP level positively correlated with metabolic syndrome in 
kidney transplantation patients. Body mass index was an independent 
predictor of serum CRP levels in kidney transplantation patients. [Tzu 
Chi Med J 2010;22(3):131–136]
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1. Introduction
C-reactive protein (CRP) is a hepatic-derived pen-
traxin that plays a key role in the innate immune 
response [1] and is an independent risk factor for renal 
allograft loss [2,3]. An elevated pre-transplant serum 
CRP level is a risk predictor for major cardiac events in 
renal transplant patients [4] and the CRP level predicts 
all-cause mortality in these patients [5]. Metabolic 
syndrome is a condition of insulin resistance [6] and 
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is considered a significant risk factor for cardiovas-
cular disease and mortality in the general population 
[7,8]. Tacrolimus and glucocorticoids are risk factors 
resulting in insulin resistance when used as treatment 
in kidney transplant patients [9,10]. Metabolic syn-
drome is a risk factor for post-transplant diabetes 
mellitus, chronic graft dysfunction, graft loss, athero-
sclerotic events and patient death in renal transplant 
recipients [11–13]. The aim of the present study, there-
fore, is to explore the relationship between serum CRP 
concentrations and the presence of metabolic syn-
drome in kidney transplant patients.
2. Materials and methods
2.1. Patients
Fifty-five kidney transplantation patients were studied 
in September 2008 in a medical center in Hualien, 
Taiwan. This group comprised 27 men and 28 women, 
who ranged in age from 40 to 61 years. The study 
was approved by the Protection of Human Subjects 
Institutional Review Board of Tzu Chi University and 
Hospital. Patients were excluded if they had an acute 
infection or if they refused to provide informed con-
sent. No kidney transplantation patients in this study 
took aspirin or other nonsteroidal anti-inflammatory 
drugs.
2.2. Anthropometric analysis
Body weight to the nearest half kilogram was mea-
sured with patients wearing only light clothing without 
shoes. Height was measured to the nearest half cen-
timeter. Waist circumference was measured to the 
nearest half centimeter at the shortest point below the 
lower rib margin and the iliac crest. The body mass 
index (BMI) was calculated as the weight (in kilograms) 
divided by the height squared (in meters). Bioimpedance 
measurements of fat mass were performed at bedside 
according to the standard tetrapolar whole body (hand-
foot) technique, using a single-frequency (50 kHz) 
analyzer (Biodynamic-450; Biodynamics Corp., Seattle, 
WA, USA). Measurements were carried out by the same 
operator; fat mass was collected and analyzed by 
specific formulae offered by the manufacturer [14,15].
2.3. Biochemical investigations
Fasting blood samples were taken from each subject. 
Approximately 0.5 mL was used to determine the 
white blood cell count (Sysmex K-1000; Sysmex Corp., 
Bohemia, NY, USA) and the remaining blood was 
immediately centrifuged at 3000g for 10 minutes for 
biochemical study. The serum was stored at 4ºC for 
biochemical examination within 1 hour after collection. 
Serum levels of creatinine, fasting glucose, total cho-
lesterol, triglycerides, high-density lipoprotein (HDL) 
cholesterol, albumin, globulin, glutamic oxaloacetic 
transaminase, glutamic pyruvic transaminase, and CRP 
were measured using an autoanalyzer (COBAS Integra 
800; Roche Diagnostics, Basel, Switzerland).
2.4. Metabolic syndrome and its 
components
The prevalence of metabolic syndrome was defined 
using the International Diabetes Federation definition 
[6]. People were classified as having metabolic syn-
drome if they had central (abdominal) obesity with a 
waist circumference ≥ 90 cm for men or ≥ 80 cm for 
women (Chinese criteria), and had two or more of the 
following criteria: fasting serum glucose ≥ 110 mg/dL, 
triglycerides ≥ 150 mg/dL, HDL cholesterol level < 40 mg/
dL in men or < 50 mg/dL in women, and blood pres-
sure ≥ 130/85 mmHg. In this analysis, a patient who 
was on antihypertensive medication was considered 
to have high blood pressure. Type 2 diabetes was 
determined according to World Health Organization 
criteria [16]. A person was regarded as diabetic if fast-
ing plasma glucose was ≥ 126 mg/dL, if 2-hour glucose 
from an oral glucose tolerance test was ≥ 200 mg/dL, 
or if they were on diabetes medication (oral or insulin).
2.5. Statistical analysis
Data are expressed as mean ± standard deviation and 
tested for normal distribution by Kolmogorov-Smirnov 
statistics. Categorical variables were analyzed by the 
χ2 test. Comparisons between patients were performed 
using Student’s independent t test (two-tailed) for 
normally distributed data or the Mann-Whitney U test 
for parameters with non-normal distribution (fasting 
glucose, CRP and creatinine). Clinical variables that 
correlated with CRP in kidney transplantation patients 
were evaluated by univariate linear regression analyses. 
Variables that were significantly associated with CRP 
in kidney transplantation patients were tested for in-
dependence in multivariate forward stepwise regres-
sion analysis. Data were analyzed using SPSS version 
13.0 (SPSS Inc., Chicago, IL, USA) for Windows. A 
p value < 0.05 was considered statistically significant.
3. Results
The clinical and laboratory characteristics of the kid-
ney transplantation patients are presented in Tables 1 
and 2. Their medical histories included diabetes 
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(n = 17; 30.9%), hypertension (n = 34; 61.8%), and 
hyperlipidemia (n = 17; 30.9%). The use of drugs in-
cluded angiotensin receptor blockers (n = 22; 40.0%), 
calcium channel blockers (n = 22; 40.0%), β-blockers 
(n = 6; 10.9%), sulfaurea (n = 10; 18.2%), metformin 
(n = 6; 10.9%), insulin (n = 7; 12.7%), tacrolimus (n = 36; 
65.5%), mycophenolate mofetil (n = 19; 34.5%), myc-
ophenolic acid (n = 21; 38.2%), steroids (n = 38; 69.1%), 
rapamycin (n = 7; 12.7%), and cyclosporine (n = 13; 
23.6%). None of these patients used angiotensin-
converting enzyme inhibitors, peroxisome proliferator-
activated receptor-γ (PPAR-γ) agonists or fibrates.
The clinical characteristics and fasting serum CRP 
levels of the 55 kidney transplantation patients are 
presented in Table 2. Thirteen patients (23.6%) had 
metabolic syndrome. Kidney transplantation patients 
with metabolic syndrome had higher CRP levels than 
those without this syndrome (p = 0.001). CRP levels 
did not differ statistically by sex distribution, diabetes, 
hypertension, hyperlipidemia, or use of any of the 
abovementioned drugs. Univariate linear analysis of 
fasting serum CRP levels in kidney transplantation pa-
tients is presented in Table 3. Body weight (p = 0.001), 
waist circumference (p = 0.008), BMI (p < 0.001), and 
body fat mass (p = 0.042) were positively correlated 
with serum CRP levels in these patients.
Multivariate forward stepwise linear regression 
analysis of the significant variables showed that BMI 
(β = 0.455, R2 = 0.207, p < 0.001) was an independent 
predictor of serum CRP levels in kidney transplanta-
tion patients (Table 4).
Table 1 — Clinical and analytical characteristics of the 
55 kidney transplantation patients*
Anthropometric data
   Age (yr) 50.16 ± 10.34
   Body weight (kg) 60.52 ± 13.79
   Height (cm) 161.25 ± 9.13
   BMI (kg/m2) 23.34 ± 4.18
   Waist circumference (cm) 82.11 ± 10.82
   Body fat mass (%) 20.37 ± 8.39
   KT duration (mo) 43.64 ± 40.69
Biochemical data
   Albumin (g/dL) 4.43 ± 0.34
   Triglyceride (mg/dL) 130.07 ± 60.30
   HDL cholesterol (mg/dL) 56.42 ± 16.34
   Total cholesterol (mg/dL) 198.18 ± 52.02
   GOT (IU/L) 19.44 ± 5.58
   GPT (IU/L) 17.80 ± 8.90
   WBC (×1000/μL) 6.33 ± 1.88
   Globulin (g/dL) 2.84 ± 0.49
   Fasting glucose (mg/dL) 113.00 ± 50.86
   Creatinine (mg/dL) 1.80 ± 6.91
   CRP (mg/dL) 0.27 ± 0.40
*Data are presented as mean ± standard deviation. BMI = body mass 
index; KT = kidney transplantation; HDL = high-density lipoprotein; GOT = 
glutamic oxaloacetic transaminase; GPT = glutamic pyruvic transami-
nase; WBC = white blood cell count; CRP = C-reactive protein.
4. Discussion
The results of our study showed that CRP level was 
positively associated with metabolic syndrome in kid-
ney transplantation patients. BMI was an independent 
predictor of serum CRP levels in these patients.
Metabolic syndrome is a constellation of physical 
and laboratory abnormalities including hyperten-
sion, hyperglycemia, hyperlipidemia, and abdominal 
obesity [6]. It constitutes a major health problem in 
the West and is estimated to affect at least 20% of 
the adult population [17]. Post-transplant metabolic 
syndrome is comprised of hypertension, dyslipidemia, 
increased fat mass/obesity, and glucose intolerance, 
combined with other metabolic side effects derived 
from glucocorticoid and calcineurin inhibitor immu-
nosuppression [10]. Tacrolimus use is also a risk factor 
for insulin resistance in kidney transplant recipients 
[9]. The prevalence of metabolic syndrome in the 
present study was 23.6%. These findings are in agree-
ment with other studies in Asia [18,19], which re-
ported prevalences ranging from 23.8% to 26.0% 
for subjects in Japan and Hong Kong.
CRP is an acute phase marker whose blood levels 
depend on interleukin-6 and other inflammatory pro-
teins that stimulate its production in hepatocytes, 
lymphocytes, alveolar macrophages and monocyte-
derived macrophages [20]. CRP impairs insulin sign-
aling, contributes to atherothrombosis, and is as sociated 
with insulin resistance, adiposity and metabolic syn-
drome [21]. High CRP levels have been related to risk 
factors for dyslipidemia, hypertension, diabetes mel-
litus, and obesity [22].
CRP concentration is directly related to the volume 
of visceral fat as determined by magnetic resonance 
imaging [23]. Abdominal adiposity was associated 
with significantly elevated CRP values in non-obese 
people [24]. A higher BMI as well as central obesity 
were independently associated with higher levels of 
CRP in Taiwan [25]. BMI, body weight and fat mass also 
correlated positively with serum CRP in kidney trans-
plantation patients [26]. Another study noted that 
waist circumference was an independent determinant 
of CRP in renal transplant recipients [27]. Our study 
noted that body weight, waist circumference, BMI, and 
body fat mass were positively correlated with fasting 
serum CRP levels in kidney transplantation patients. 
CRP concentration had no correlation with HDL cho-
lesterol, triglycerides, fasting glucose, age, kidney 
transplantation duration, albumin, globulin or total 
cholesterol in our study. Multivariate forward stepwise 
linear regression analysis of the significant variables 
showed that BMI was an independent predictor of 
fasting serum CRP levels in our study.
Pharmacological interventions have been shown to 
influence serum CRP levels in humans. A meta-analysis 
showed that statins can reduce serum CRP levels, 
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Table 2 — Clinical characteristics and fasting serum C-reactive protein (CRP) levels of the 55 kidney transplantation 
patients
 n (%) CRP (mg/dL) p
Sex
 Male 27 (49.1) 0.23 ± 0.32 0.852
 Female 28 (50.9) 0.32 ± 0.46
Diabetes
 No 38 (69.1) 0.25 ± 0.38 0.380
 Yes 17 (30.9) 0.33 ± 0.44
Hypertension
 No 21 (38.2) 0.13 ± 0.14 0.187
 Yes 34 (61.8) 0.37 ± 0.48
Hyperlipidemia 
 No 38 (69.1) 0.19 ± 0.25 0.394
 Yes 17 (30.9) 0.34 ± 0.48
Metabolic syndrome 
 No 42 (76.4) 0.18 ± 0.32 0.001*
 Yes 13 (23.6) 0.58 ± 0.49
Angiotensin receptor blocker use 
 No 33 (60.0) 0.18 ± 0.26 0.141
 Yes 22 (40.0) 0.43 ± 0.53
Calcium channel blocker use
 No 33 (60.0) 0.21 ± 0.35 0.230
 Yes 22 (40.0) 0.37 ± 0.46
β-blocker use
 No 49 (89.1) 0.24 ± 0.32 0.553
 Yes 6 (10.9) 0.54 ± 0.79
Statin use
 No 38 (69.1) 0.21 ± 0.30 0.076
 Yes 17 (30.9) 0.42 ± 0.54
Sulfaurea use
 No 45 (81.8) 0.27 ± 0.39 0.403
 Yes 10 (18.2) 0.32 ± 0.43
Metformin use
 No 49 (89.1) 0.27 ± 0.38 0.948
 Yes 6 (10.9) 0.33 ± 0.54
Insulin use
 No 48 (87.3) 0.27 ± 0.39 0.757
 Yes 7 (12.7) 0.33 ± 0.49
Cyclosporine use 
 No 42 (76.4) 0.21 ± 0.30 0.889
 Yes 13 (23.6) 0.42 ± 0.54
Tacrolimus use 
 No 19 (34.5) 0.31 ± 0.45 0.741
 Yes 36 (65.5) 0.26 ± 0.37
Mycophenolate mofetil use 
 No 36 (65.5) 0.27 ± 0.40 0.950
 Yes 19 (34.5) 0.29 ± 0.41
Mycophenolic acid use 
 No 34 (61.8) 0.34 ± 0.47 0.237
 Yes 21 (38.2) 0.17 ± 0.22
Steroid use 
 No 17 (30.9) 0.25 ± 0.34 0.732
 Yes 38 (69.1) 0.29 ± 0.43
Rapamycin use 
 No 48 (87.3) 0.26 ± 0.37 0.861
 Yes 7 (12.7) 0.37 ± 0.58
Hepatitis B 
 No 47 (85.5) 0.31 ± 0.42 0.206
 Yes 8 (14.5) 0.10 ± 0.11
Hepatitis C
 No 52 (94.5) 0.29 ± 0.41 0.087
 Yes 3 (5.5) 0.04 ± 0.02
*p < 0.05, Mann-Whitney U test.
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independent of the type and dose of statin used [28]. 
However, one study showed that atorvastatin 10 mg/
day did not alter CRP levels after 3 months of treat-
ment in kidney transplant recipients [29]. PPAR-α ac-
tivation by fibrates also impairs proinflammatory 
cytokine-signaling pathways in the liver, resulting in 
the modulation of the acute phase response reaction 
via mechanisms independent of changes in lipopro-
tein levels [30]. PPAR-γ agonist treatment results in 
decreased plasma levels of CRP in both obese patients 
and patients with type 2 diabetes [31]. In one study, 
CRP level was significantly decreased in kidney trans-
plantation patients who used angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers 
[32]. Mycophenolate mofetil use correlates inversely 
with CRP levels in renal transplant recipients [33]. None 
of our study patients used angiotensin-converting 
enzyme inhibitors, PPAR-γ agonists or fibrates. Our 
results did not show a relationship between any drug 
therapy and serum CRP concentration in kidney trans-
plantation patients.
There were some limitations in our study. First, this 
study had a cross-sectional design. Therefore, our 
findings should be investigated in long-term prospec-
tive studies before a causal relationship between 
serum CRP and metabolic syndrome in kidney trans-
plantation patients can be established. Second, there 
was a lack of serum insulin or insulin resistance in 
this study. Another limitation is that this study did not 
check other inflammatory markers such as tumor 
necrosis factor-α, interleukin-6 and interleukin-12. 
Further studies are needed to show the association 
between metabolic syndrome and serum CRP levels 
in kidney transplantation patients.
In conclusion, serum CRP concentration correlates 
positively with metabolic syndrome in kidney trans-
plantation patients. BMI was an independent predic-
tor of serum CRP levels in kidney transplantation 
patients.
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